We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Direct Reprogramming of Fibroblasts into Melanocytes Avoids Cancer Threat

By LabMedica International staff writers
Posted on 29 Dec 2014
A team of cell biologists has successfully induced fibroblasts to convert to functional melanocytes (melanin-producing skin cells) without going through a preliminary pluripotent stage.

Direct reprogramming provides a fundamentally new approach for the manufacture of patient-specific cells that greatly reduces the danger of inadvertently generating tumors. More...
In the current study, investigators at the University of Pennsylvania (Philadelphia, USA) and their colleagues devised a method for directly reprogramming fibroblasts into functional melanocytes.

The first step was to identify 10 specific cell transcription factors linked to melanocyte development. Transcription factor screening assays revealed that three transcription factors - SOX10 (sex determining region Y-box 10), MITF (microphthalmia-associated transcription factor), and PAX3 (paired box 3) - out of those 10 were sufficient to induce fibroblasts to transform into melanocytes.

Results published in the December 16, 2014, online edition of the journal Nature Communications revealed that induced melanocytes (iMels) produced by this technique activated melanocyte-specific networks, expressed components of the pigment production and delivery system, and produced melanosomes. Human iMels properly integrated into the dermal-epidermal junction and produced and delivered melanin pigment to surrounding keratinocytes in a three-dimensional organotypic skin reconstruct. Furthermore, human iMels generated pigmented epidermis and hair follicles in skin reconstitution assays in vivo.

"We did a huge amount of work," said senior author Dr. Xiaowei Xu, associate professor of pathology and laboratory medicine at the University of Pennsylvania. "We eliminated all the combinations of the other transcription factors and found that these three are essential. Through direct reprogramming, we do not have to go through the pluripotent stem cell stage, but directly convert fibroblasts to melanocytes. So these cells do not have tumorigenicity. By generating melanocytes from the fibroblasts of melanoma patients, we can screen not only to find why these patients easily develop melanoma, but possibly use their cells to screen for small compounds that can prevent melanoma from happening."

Related Links:
University of Pennsylvania


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
New
HPV Test
Allplex HPV28 Detection
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.